The 5HT1A receptor system: Possible implications for schizophrenic negative symptomatology

Psychiatric Annals

Volumn 26, Issue 2, 1996, Pages 88-92

  Sharma, Rajiv P ^a,b   Shapiro, Lisa E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Psychiatric Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030545420     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19960201-09     Document Type: Article

References (48)

1. Petrovichy P. Reticular formation and its raphe system, I: cytoarchitectonics with comparative aspects. Acta Univ Carol [Med] (Praha). 1980; 99:1-117.
2. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol. 1978; 179:641-668.
3. 1A recognition sites. Brain Res. 1986; 376:85-96.
4. 1A receptors in the human brain postmortem. Brain Res. 1994; 658:55-59.
5. Peroutka S, Schmidt AW. An overview of 5-hydroxytryptamine receptor families. In: Sandler M, Coppen A, Harnett S, eds. 5-Hydroxytryptamine in Psychiatry. London: Oxford University Press; 1991:2-22.
6. McCormick DA, Williamson A. Convergence and divergence of neurotransmitter action in human cerebral cortex. Proc Natl Acad Sci USA. 1989; 86:8098-8102.
7. 1A receptor agonist 8-OH-DPAT on the release of 5HT in dorsal and median raphe innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 1991; 48:1779-1786.
8. 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5HT autoreceptors in rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1988; 338:463-471.
9. 1A receptor. Eur J Pharmacol. 1988; 157:173-181.
10. 1A autoreceptors of the dorsal and median raphe nuclei. J Pharmacol Exp Ther. 1994;269(3):1268-1279.
11. 1B agonists. Synapse. 1987; 1:3-9.
12. Davis M, Cassella JV, Wren WH, Kehne JH. Serotonin receptor subtype agonists: differential effects on sensorimotor reactivity measured with acoustic startle. Psychopharmacol Bull. 1986; 22:837-843.
13. Svensson L, Ahlenius S. Enhancement by the putative 5HT receptor agonist 8-OH-2(di-n-propylamino)tetralin of the acoustic startle response in the rat. Psychopharmacology. 1983; 79:104-107.
14. Engel JA, Hjorth S, Svensson K, Carlsson A, Liljequist S. Anticonflict effect of the putative serotonin receptor agonist 8-OH-DPAT. Eur J Pharmacol. 1984; 105:365-368.
15. Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE. Behavioral studies with anxiolytic drugs, VI: effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther. 1989; 250:809-817.
16. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol. 1989; 169:1-10.
17. 1A receptor binding in rat brain. Pharmacol Biochem Behav. 1992; 42:25-28.
18. Hillegaart V. Functional topography of brain serotonergic pathways in the rat. Acta Physiol Scand. 1991; 142(suppl 598):7-53.
19. 1A receptor agonists. Eur J Pharmacol. 1991; 193:351-356.
20. Wieland S, Fischette CT, Lucki I. Chronic infusion of tandospirone and imipramine alters 5HT mediated behaviors and 5HT receptors. Soc Neurosci. 1990; 16:530. Abstract.
21. Glennon RA, Darmani NA, Martin BR. Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. Life Sci. 1991; 48:2493-2498.
22. 1A receptors. Br J Pharmacol. 1990; 100:793-799.
23. Costall B, Naylor RJ, Marsden CD, Pycock CJ. Serotonergic modulation of the dopamine response from the nucleus accumbens. J Pharm Pharmacol. 1976; 28:523-526.
24. 1A agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain stimulation reward. J Neural Transm. 1991; 83:139-148.
25. 1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther. 1994;268(3):1297-1303.
26. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther. 1990;253(2):803-811.
27. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol. 1993a; 347:353-362.
28. Arborelius L, Nomikos GG, Hacksell U, Svensson TH. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand. 1993b; 148:460-466.
29. Meltzer HY, Nash FJ VII. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev. 1991; 43:4.
30. Neal-Beliveau BS, Joyce JN, Lucki I. Serotonergic involvement in haloperidol induced catalepsy. J Pharmacol Exp Ther. 1993; 265(1):207-217.
31. McMillen BA, Mattiace LA. Comparative neuropharmacology of buspirone and MJ-13805, a potential antianxiety drug. J Neural Transm. 1983; 57:255-265.
32. Davies M, Sloley BD, Fletcher PJ. Neurochemical, electrophysiological and behavioral evidence that 8-OH-DPAT stimulates central dopamine systems. Soc Neurosci. 1989; 15:225. Abstract.
33. 1A receptor agonist, reduces the immobility of rats in the forced swimming test by acting on the nucleus raphe dorsalis. Eur J Pharmacol. 1988; 158:53-59.
34. Fletcher P. Dopamine receptor blockade in nucleus accumbens or caudate nucleus differentially affects feeding induced by 8-OH-DPAT injected into dorsal or median raphe. Brain Res. 1991; 552:181-189.
35. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull. 1990; 16(3):425-432.
36. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991;48:355-363.
37. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993; 8(4):315-336.
38. 2 receptor binding in patients with chronic schizophrenia. Psychopharma-cology. 1993; suppl:35-39.
39. Sathananthan GL, Sanghvi I, Phillips N, Gershon S. MJ 9022: correlation between neuroleptic potential and stereotypy. Curr Ther Res. 1975; 18(5):701-705.
40. Sovner R, Pamell-Sovner N. Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol. 1989;9(1):61-62.
41. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol. 1991;11(3):193-197.
42. Brody D, Adler LA, Kim T, Rotrosen J. Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol. 1990; 10:68-69.
43. D'Mello DA, McNeil JA, Harris W. Buspirone suppression of neuroleptic induced akathisia: multiple case reports. J Clin Psychopharmacol. 1989;9(2):151-152.
44. 2 antagonists on haloperidol induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5HT dopamine interactions. Psychopharmacology. 1989; 97:456-461.
45. Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1993; 13(3):204-209.
46. Rao ML, Möller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologie treatment. Neuropsychobiology. 1994; 30:160-172.
47. 1A receptors in human brain tissue. Eur J Pharmacol. 1992; 221:397-398.
48. 2 receptors of normal human brain in vitro. Eur J Pharmacol. 1987; 143:279-282.